title: Glucagon-like peptide-1 receptor agonist administration suppresses both water and saline intake in rats.
abstract: Glucagon-like peptide-1 (GLP-1) plays an important role in energy homeostasis. Injections of GLP-1 receptor (GLP-1R) agonists suppress food intake, and endogenous GLP-1 is released when nutrients enter the gut. There is also growing evidence that the GLP-1 system is involved in the regulation of body fluid homeostasis. GLP-1R agonists suppress water intake independent of their effects on food intake. It is unknown, however, whether this suppressive effect of GLP-1R agonists extends to saline intake. Accordingly, we tested the effect of the GLP-1R agonists liraglutide (0.05 μg) and exendin-4 (0.05 μg) on water and saline intake, as stimulated either by angiotensin II (AngII) or by water deprivation with partial rehydration (WD-PR). Each agonist suppressed AngII-induced water intake; however, only exendin-4 suppressed saline intake. WD-PR-induced water and saline intakes were both attenuated by each agonist. Analysis of drinking microstructure after WD-PR found a reliable effect of the agonists on burst number. Furthermore, exendin-4 conditioned a robust taste avoidance to saccharine; however, there was no similar effect of liraglutide. To evaluate the relevance of the conditioned taste avoidance, we tested whether inducing visceral malaise by injection of lithium chloride (LiCl) suppressed fluid intake. Injection of LiCl did not suppress water or saline intakes. Overall, these results indicate that the fluid intake suppression by GLP-1R activation is not selective to water intake, is a function of post-ingestive feedback, and is not secondary to visceral malaise.
authors: Behavioral Neuroscience Program, Department of Psychology, The State University of New York at Buffalo, Buffalo, NY, USA.
authors: N J
authors: NJ
authors: McKay
authors: D
authors: D
authors: Daniels
mesh_terms: D000818:Animals; D000067757:Glucagon-Like Peptide-1 Receptor; D018021:Lithium Chloride / Q000494:pharmacology; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D018027:Receptors, Glucagon / Q000819:agonists*; D017673:Sodium Chloride, Dietary / Q000008:administration & dosage*; D014867:Water
chemical_list: C000593835:Glp1r protein, rat; D000067757:Glucagon-Like Peptide-1 Receptor; D018027:Receptors, Glucagon; D017673:Sodium Chloride, Dietary; D014867:Water; D018021:Lithium Chloride
keywords: exendin-4; fluid intake; liraglutide; thirst
references: J Pharmacol Exp Ther. 2006 Feb;316(2):852-9
references: 16221740
references: Behav Neurosci. 1992 Feb;106(1):217-28
references: 1554433
references: Endocrinology. 2009 Apr;150(4):1680-7
references: 19074583
references: Am J Physiol. 1998 Jan;274(1):R23-9
references: 9458894
references: J Biol Chem. 1990 May 15;265(14):8001-8
references: 1692320
references: Physiol Behav. 1980 May;24(5):979-82
references: 7403301
references: Brain Res. 2010 Sep 2;1350:18-34
references: 20353764
references: J Neurosci. 2011 Oct 12;31(41):14453-7
references: 21994361
references: Clin Ther. 2011 May;33(5):528-76
references: 21665041
references: Eur J Pharmacol. 1975 Mar;31(1):110-4
references: 1126371
references: Obesity (Silver Spring). 2011 Jul;19(7):1342-9
references: 21415845
references: JAMA. 2007 Jul 11;298(2):194-206
references: 17622601
references: Neuropharmacology. 2012 Apr;62(5-6):1916-27
references: 22227019
references: Cell Metab. 2011 Mar 2;13(3):320-30
references: 21356521
references: J Neurosci. 2002 Dec 1;22(23):10470-6
references: 12451146
references: Pflugers Arch. 1983 Feb;396(2):106-9
references: 6835812
references: Psychopharmacology (Berl). 1978 May 31;57(3):289-94
references: 97711
references: J Neurochem. 1996 Nov;67(5):1982-91
references: 8863504
references: Am J Physiol. 1987 Apr;252(4 Pt 2):R754-9
references: 3551636
references: Diabetes. 2001 Nov;50(11):2530-9
references: 11679431
references: J Clin Endocrinol Metab. 2003 Jul;88(7):3082-9
references: 12843147
references: Nature. 1996 Jan 4;379(6560):69-72
references: 8538742
references: Appetite. 2001 Feb;36(1):84-92
references: 11161348
references: Am J Physiol Regul Integr Comp Physiol. 2003 Jun;284(6):R1427-35
references: 12776726
references: Digestion. 2006;73(2-3):142-50
references: 16809911
references: Psychoneuroendocrinology. 2013 Aug;38(8):1259-70
references: 23219472
references: J Neurosci. 2000 Feb 15;20(4):1616-21
references: 10662851
references: Physiol Behav. 1996 Oct;60(4):1099-104
references: 8884939
references: J Comp Neurol. 1988 May 22;271(4):519-32
references: 3385016
references: Physiol Rev. 2007 Oct;87(4):1409-39
references: 17928588
references: J Endocrinol. 1993 Jul;138(1):159-66
references: 7852887
references: Am J Physiol Regul Integr Comp Physiol. 2007 Oct;293(4):R1495-503
references: 17670858
references: Scand J Gastroenterol. 1996 Jul;31(7):665-70
references: 8819215
references: Am J Med. 2011 Jan;124(1 Suppl):S3-18
references: 21194578
references: Am J Physiol Regul Integr Comp Physiol. 2011 Dec;301(6):R1755-64
references: 21975647
references: Am J Physiol Regul Integr Comp Physiol. 2005 Jun;288(6):R1695-706
references: 15718384
references: J Comp Neurol. 1999 Jan 11;403(2):261-80
references: 9886047
references: J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29
references: 19801361
references: Diabetologia. 2002 Feb;45(2):195-202
references: 11935150
references: Lancet. 2009 Jul 4;374(9683):39-47
references: 19515413
references: Acta Pharmacol Toxicol (Copenh). 1983 Feb;52(2):81-5
references: 6846024
references: Diabetes. 2008 Aug;57(8):2046-54
references: 18487451
references: Pharmacol Biochem Behav. 1997 Nov;58(3):673-7
references: 9329057
references: Am J Physiol. 1996 Oct;271(4 Pt 2):R848-56
references: 8897973
references: Neuroscience. 1997 Mar;77(1):257-70
references: 9044391
references: J Clin Invest. 2002 Jul;110(1):43-52
references: 12093887
references: Proc Soc Exp Biol Med. 1998 Oct;219(1):85-91
references: 9751227